1. No emergence of resistance mutations in COVID‐19 patients receiving nirmatrelvir/ritonavir.
- Author
-
Palomino‐Cabrera, Rosalía, Tejerina, Francisco, Molero‐Salinas, Andrea, Veintimilla, Cristina, Catalán, Pilar, Ferris, María, Osorio, Santiago, Alonso, Roberto, Muñoz, Patricia, de García de Viedma, Darío, and Pérez‐Lago, Laura
- Subjects
COVID-19 ,SARS-CoV-2 - Abstract
A study published in the Journal of Medical Virology examined the emergence of resistance mutations in COVID-19 patients receiving the antiviral drug nirmatrelvir/ritonavir. The study analyzed 60 patients who received the drug and found that none of the known resistance mutations were identified in the patients. However, low-frequency substitutions and fixed mutations were observed in some patients, particularly those who were immunosuppressed. The study suggests that the emergence of resistance mutations to nirmatrelvir/ritonavir is currently rare. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF